Teduglutide , ≥98% , 197922-42-2
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB1313.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| solubility | Methanol (Slightly), Water (Slightly) |
| form | Solid |
| color | White to Off-White |
| Stability: | Hygroscopic |
| InChIKey | CILIXQOJUNDIDU-ASQIGDHWSA-N |
Description and Uses
Teduglutide was approved in August 2012 by the European Commission and in December 2012 by the US FDA for the treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral nutrition (PN). Teduglutide (also known as ALX-0600) is a GLP-2 analogue in which glycine has been substituted for alanine at position 2 from the N-terminus, thereby conferring resistance to degradation by DPP-4. Teduglutide has similar binding affinity, agonist potency, and agonist efficacy as GLP-2 in assays with the rat GLP-2 receptor. Administration of teduglutide to rats gave a significant increase in small intestine weight and an increase in the height of intestinal villi. Teduglutide was prepared by solid-phase peptide synthesis.
Treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease (glucagon-like peptide-2 (GLP- 2) analog).
